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Background: Cognitive impairment may be a risk factor for, as well as a consequence 
of, psychosis. Non-remitting symptoms, premorbid functioning, level of education, and 
socioeconomic background are known correlates. A possible confounder of these 
associations is substance use, which is common among patients with psychosis and 
linked to worse clinical outcomes. Studies however show mixed results for the effect 
of substance use on cognitive outcomes. In this study, the long-term associations of 
substance use with cognition in a representative sample of first-episode psychosis 
patients were examined.
Methods: The sample consisted of 195 patients. They were assessed for symptom levels, 
function, and neurocognition at 1, 2, 5, and 10 years after first treatment. Test scores were 
grouped into factor analysis-based indices: motor speed, verbal learning, visuomotor 
processing, verbal fluency, and executive functioning. A standardized composite score of 
all tests was also used. Patients were divided into four groups based on substance-use 
patterns during the first 2 years of treatment: persistent users, episodic users, stop-users, 
and nonusers. Data were analyzed using linear mixed effects modeling.
Results: Gender, premorbid academic functioning, and previous education were the 
strongest predictors of cognitive trajectories. However, on motor speed and verbal 
learning indices, patients who stopped using substances within the first 2 years of 
follow-up improved over time, whereas the other groups did not. For verbal fluency, 
the longitudinal course was parallel for all four groups, while patients who stopped 
using substances demonstrated superior performances compared with nonusers. 
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INTRODUCTION
Cognitive impairment is a core feature of schizophrenia. It is 
observed in the majority of patients (1, 2), often present before 
the onset of psychosis and is also prevalent in non-affected 
relatives (3, 4). It is associated with negative symptoms such as 
apathy and flat affect (5, 6), and several studies have shown an 
association with poorer clinical and functional outcomes (7). 
Previous studies report deficits in both processing speed and 
episodic memory (8), as well as working memory, executive 
functions (9), and attention (10). One meta-analysis (11) showed 
moderate to large effect sizes across all cognitive domains, with 
impairments being more pronounced in older and more chronic 
patients. Correlates of cognitive impairments include premorbid 
intellectual functioning, level of education, social functioning, 
and socioeconomic status (12–14). It has also been suggested 
that the prevalent long-term use of antipsychotic medication in 
schizophrenia spectrum disorders could compromise cognitive 
functioning (15, 16). However, studies with short follow-up 
intervals have also found indications of cognitive improvement 
associated with the use of antipsychotics (17–19).
A possible confounder in the relationship between cognitive 
impairments and outcome is substance use, which is common 
in patients with psychosis. Reported prevalence rates of 
concurrent substance use converge on 50%, significantly higher 
than rates in the general population (20–22). Experimental 
studies have shown that tetrahydrocannabinol transiently 
induces psychotic symptoms in a dose-dependent manner and 
cognitive impairment in healthy individuals (23). Cannabis use 
is also consistently associated with more cognitive impairments 
in studies of schizophrenia (24); however, there are some 
contradictory findings. Several cross-sectional studies have found 
superior performance in visual memory, working memory, and 
executive functioning (25–30), attention (31), and, in overall, 
cognitive task performance in substance-using compared with 
the performance in non-using patients (12, 13, 32). Long-term 
longitudinal studies of cognition in psychosis are scarce, and very 
few extend beyond a 5-year follow-up (33–42). Overall findings 
indicate stable impairment over time. Studies focusing explicitly 
on the role of substance use appear to be lacking.
Several studies have reported that continued substance 
use leads to poorer outcomes than those who stop substances 
early on in their course of treatment (43, 44). Cessation of use 
is associated with improvements in symptoms, depression, and 
functioning (45–47). To our knowledge, no studies have focused 
on substance-use cessation and the effect on cognition in first-
episode psychosis (FEP) patients.
The early Treatment and Intervention in Psychosis (TIPS) 
study is a prospective, longitudinal study that originally sets out 
to investigate the relationship between duration of untreated 
psychosis (DUP) and outcome in FEP patients. It includes a 
very rich database of the development of significant clinical 
characteristics from the first week of treatment. We have 
previously shown that substance users who stopped using during 
the first 2 years of treatment show a different illness trajectory than 
those who continue using or stopped using at a later point in time 
(47). Substance users had better social premorbid functioning 
than nonusers (NUs) (48). Cognition, in general, appeared to 
be stable over the first 10 years in treatment (39) in our sample, 
also with regard to clinical subsamples (39) and using improved 
statistical methods (49). Improved verbal memory and learning 
at 1- and 2-year follow-up was associated with fewer relapses 
during the first year of treatment (50), and follow-up analyses 
of subsamples suggested that patients who relapsed during the 
first year of treatment had different cognitive trajectories over the 
10-year period (39).
The aim of the current study is to examine the long-term (10-
year) associations between substance use and cognition as well 
as the effect of early substance-use discontinuation in the TIPS 
sample. Based on our extensive data material, we will also take 
into account potential predictive or confounding factors such 
as premorbid functioning, clinical symptoms, and diagnostic 
groups (narrow versus broad schizophrenia spectrum).
MATERIAL AND METHODS
Study Design
The TIPS study is a prospective, longitudinal follow-up of a large, 
clinical epidemiological cohort recruited consecutively over 4 
years from four Scandinavian health care sectors during 1997–
2000. These include two sectors in Rogaland County, Norway, the 
Ullevål sector in Oslo County, Norway, and a sector from Roskilde 
County, Denmark. The combined estimated population at the start 
Persistent users demonstrated impaired visuomotor processing speed compared with 
nonusers. Within the stop- and episodic use groups, patients with narrow schizophrenia 
diagnoses performed worse compared with patients with other diagnoses on verbal 
learning and on the overall composite neurocognitive index.
Discussion: This study is one of very few long-term studies on cognitive impairments in 
first-episode psychosis focusing explicitly on substance use. Early cessation of substance 
use was associated with less cognitive impairment and some improvement over time 
on some cognitive measures, indicating a milder illness course and superior cognitive 
reserves to draw from in recovering from psychosis.
Keywords: psychosis, substance use, cognition, neurocognition, first-episode psychosis
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of the study period was 665,000 inhabitants. Health care services 
were catchment area based and publicly funded in all sectors. The 
areas were similar sociodemographically (e.g. urbanicity, mean 
educational and income levels, and opportunities for employment) 
(51). Patients from all areas were treated according to a 2-year 
standard treatment protocol that included antipsychotic medication, 
supportive psychotherapy, and multi-family psycho-education.
Participants
The sample consisted of FEP patients with Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition schizophrenia, 
schizophreniform disorder or schizoaffective disorder (“narrow 
schizophrenia spectrum”), delusional disorder, mood disorder with 
mood-incongruent psychotic features, brief psychotic disorder, or 
psychosis not otherwise specified (“broad schizophrenia spectrum”) 
(51, 52). Participants had to reside in one of the participating sites 
and were 15–65 years of age in Rogaland or 18–65 years in Oslo/
Roskilde and within the normal range of intellectual capacity 
(Wechsler Adult Intelligence Scale—Revised-based IQ estimate 
>70). Participants were included between 1997 and 2001 (baseline) 
and followed up at 1-, 2-, 5-, and 10 years. Twenty-three percent of 
those who were eligible declined participation. Within the group 
of 301 who consented to participate, the current sample consists 
of those who completed cognitive testing at baseline (n = 218) 
who had data for substance-use grouping (n = 195). There were no 
statistically significant differences in symptom levels, age, gender, 
premorbid functioning, or diagnostic distribution between those 
who did and those who did not complete testing at baseline. A 
total of 87% completed at least two neuropsychological tests, and 
22% completed all five follow-ups. There were 138, 137, 82, and 
85 participants who completed neurocognitive testing at each 
follow-up point. Dropout analyses did not show any statistical 
differences with regard to diagnoses, gender, duration of untreated 
psychosis (DUP), substance use, symptom levels, premorbid 
functioning, or age at 1-, 2-, 5-, or 10-year follow-up. However, 
5- and 10-year follow-up dropouts had higher excitative symptom 
component scores at baseline. Also, participants who dropped out 
in the course of the study had better scores on the trail making tests 
(visuomotor processing) compared with those who only completed 
one test (t = 3.7; df: 44.4; p < .001).
Assessments
The Structured Clinical Interview for the Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (severe combined 
immunodeficiency) (53) was used for diagnostic purposes. All 
included patients were assessed using the global assessment of 
functioning (GAF) split into symptom and function scores (54). 
Demographic data, including family history of mental illness, was 
collected for all study-eligible patients. DUP was measured as 
weeks from the emergence of positive psychotic symptoms to the 
start of adequate treatment, defined as structured treatment with 
antipsychotic medication or the admission to psychiatric wards 
for psychosis. A few non-admitted patients started outpatient 
psychotherapy structured and directed toward psychosis but 
did not want medication initially. For these patients, start of 
psychotherapy was regarded as the start of adequate treatment. 
Symptom levels were measured by the positive and negative 
syndrome scale (PANSS) (53), scored on five symptom domains: 
positive, negative, cognitive, depressive, and excitative symptoms 
(55). Items constituting these components are as follows: positive 
component items P1 delusions, P3 hallucinatory behavior, P5 
grandiosity, P6 suspiciousness, and general scale item G9 unusual 
thought content; negative component N1 blunted affect; N2 
emotional withdrawal; N3 poor rapport; N4 passive withdrawal; 
and general scale items G7 motor retardation, G13 disturbance of 
volition, and G16 active social withdrawal; cognitive component 
items P2 conceptual disorganization, N5 difficulty in abstract 
thinking, N6 lack of spontaneity and flow of conversation and 
general scale items G10 disorientation, G11 poor attention and 
G15 preoccupation; depressive component general scale items G1 
somatic concern, G2 anxiety, G3 guilt feelings, G4 tension and 
G6 depression; and excitative component items P4 excitement, 
P7 hostility, and general scale items G8 uncooperativeness and 
G14 poor impulse control. Onset of FEP positive symptoms was 
defined as a PANSS score of 4 or higher on any of the PANSS 
positive component items; not previously receiving adequate 
treatment for psychosis defined as antipsychotic medication of 3.5 
haloperidol equivalents for 12 weeks or until remission of psychotic 
symptoms. Remission was defined as subthreshold symptoms for 
at least 7 days, whereas relapse involved reappearance of positive 
symptoms (items 1, 3, 5, 6, or general scale item 9) for at least 
7 days. Stable remission was defined as no relapse in the first year 
after admission (53–55).
Premorbid functioning was measured by the premorbid 
adjustment scale (56), covering two areas of functioning—
school adaptation and socialization—described through initial 
childhood level and subsequent change (57). Scores ranged from 
1 through 6 with higher scores indicating more impairment. A 
premorbid adjustment scale change score was calculated as the 
difference between childhood scores and the last score available, 
to indicate decline or improvement over time (56, 57).
Length of treatment was split into number of weeks 
of antipsychotic medication and the number of weeks of 
psychosocial treatments measured as the sum of weeks with 
uninterrupted psychosocial treatments with a frequency of once 
every fortnight or more for the first 5 years or once a month 
between 5 and 10 years.
Neurocognitive Measures
Neurocognitive tests were administered by clinical psychologists 
trained in standardized assessments or by research assistants 
supervised by a senior psychologist.
The five domains of neurocognitive functioning were:
 Verbal Learning and Delayed Recall (VL/VL index): 
The California verbal learning test (CVLT) was used to 
assess this domain, and the revised version of CVLT was 
used at 10-year follow-up (58). The number of words 
and trials were identical to the original version used at 
previous assessments, while scores were obtained for 
total immediate recall (the mean sum of trials 1–5), 
errors (the mean sum of trials 1–5), delayed free recall, 
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and perseverative responses. Combining raw scores 
obtained from these two test versions in the same 
analysis was justified as equivalency in total learning, 
and long-delay free recall raw scores is reported in 
healthy individuals (58).
 Motor Speed (MS/MS index): The finger tapping test 
with both hands was used, and the mean score for both 
the dominant and nondominant hand was calculated.
 Visuomotor Processing [trail making (TM) index]: Trail 
making (A and B) was used, with the scores representing 
total time for completion of both parts A and B.
 Executive Function index: Executive Function index 
was assessed by the Wisconsin card sorting test, PC 
version (59). The scores were “categories completed,” 
“perseveration,” “trials to first category,” and “failure to 
maintain sets.”
 Verbal Fluency index was assessed by the controlled 
oral word association task (60), where the sum mean 
scores for F-words, A-words, and S-words were used. 
At baseline, this domain also included measures 
from the digit span (with distractor) and continuous 
performance tests (number of hits) (61), but these were 
not repeated at 10-year follow-up.
For all tests, a z score was calculated based on mean scores 
at baseline. Except for finger tapping, indices were moderately 
correlated. The four indices (CVLT, TM, Wisconsin card sorting 
test, and controlled oral word association task) were therefore 
added together and averaged to form a composite index.
All cognitive ratings were done blind to the substance-use 
group affiliation of the participants. Reliability of GAF, DUP, 
and diagnosis was found satisfactory throughout the study. 
The results of the reliability assessments have been reported 
previously (62, 63).
Measurement and Classification  
of Substance Use
Substance and alcohol use was measured by the alcohol and drug 
use scale (64) using a scale from 1 to 5 (1 = no use; 2 = use without 
impairment; 3 = abuse; 4 = dependence; 5 = dependence with 
institutionalization). All commonly used illegal psychoactive 
substances were included in the assessment. We did not include 
tobacco, caffeine, or alcohol in our definition of substance use, as 
these follow different treatment paths and sequelae.
Patients were dichotomized into users or not users, where 
“use” was defined as any score >1. Abstinence is a culturally 
relevant concept in Norway, where substance use is largely 
restricted to subgroups, with any use being considered harmful. 
Patients were assessed concerning pattern of substance use 
at all follow-up points. At 5-year follow-up, we also did a 
retrospective assessment of substance use at 3 and 4 years based 
on patient information and medical charts. Patients’ substance 
use changed most during the first 2 years after inclusion; thus, 
this interval was chosen for grouping. This interval is consistent 
with prior studies (65–68).
For analyses, we grouped patients into a) nonusers (NUs), 
i.e. patients who had never used, b) stop-users (SUs), c) episodic 
users (EUs), and d) persistent users (PUs). Patients who had only 
“no-use” measurements during the first 2 years of follow-up were 
defined as nonusers (NUs). Patients who had used at baseline 
and then not use for at least two consecutive measurements, 
i.e.  at 1 and 2 years of follow-up, were defined as stop-users 
(SUs). Persistent users (PUs) used at all follow-up points, and 
episodic users (EUs) had various other substance-use patterns. 
This four-group solution was chosen based on recent studies that 
have shown that around half of substance-using patients who 
stop using appear to have less severe symptoms than those who 
continue (45). Merging previous substance users with NUs does 
not aid in understanding the impact of ceasing substance use on 
patient trajectories or prognosis.
Statistics
Statistical analyses were carried out using SPSS version 22.0 (69) 
and R version 3.4.3 (70).
Differences between groups at baseline were described 
using frequencies and percentages for categorical variables 
and means and standard deviations or medians and ranges for 
continuous variables. Comparisons between groups were made 
using chi-squared tests for categorical data and student t-tests 
for independent samples for continuous data. All tests were 
two-tailed.
To investigate the effect of substance abuse on performance 
over time, linear mixed effects models were used. The model 
uses maximum likelihood estimation to manage dropout to a 
certain degree. This is based on the assumption of dropout at 
random, that is, the probability of dropout is independent of 
future but may be dependent on previous history, which may 
be reasonable in this situation. Separate models were estimated, 
each with one of the cognitive index scores as the dependent 
variable and substance-use group as categorical predictor. 
Covariates were based on baseline differences: age, gender, years 
of education, and premorbid academic adjustment (Table 1). 
Furthermore, based on the literature, diagnostic category 
(narrow schizophrenia spectrum disorder or not) and DUP 
(log transformed due to skewed distribution) were included. 
Interaction between time and group was included in order to 
investigate whether change in neuropsychological test scores 
developed differently in the different groups. Furthermore, 
the interaction between narrow schizophrenia spectrum 
diagnoses and group was examined to determine whether 
narrow schizophrenia diagnoses are associated with different 
effects on the neuropsychological tests in the substance-use 
groups. The large data set justifies the number of parameters in 
the models. Random intercept and AR (1) was used to achieve 
a satisfactory model for correlation between longitudinal 
measurements within individuals. The executive function 
and TM indices were severely skewed to the left. In order to 
achieve a robust analysis, these data were log transformed after 
inverting the scale and adding a constant to assure positive 
values only.
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RESULTS
Table 1 outlines the demographic and clinical characteristics of 
the sample. Substance users (all) at baseline were more likely to 
be male than NUs, had poorer premorbid academic functioning, 
and shorter length of education. NUs were significantly older at 
presentation than EUs, and PUs (p = 0.001 in both groups), but 
not SUs. No differences in terms of diagnostic distribution or 
DUP were found between groups. There were no differences in 
positive or negative symptoms on the PANSS or in GAF function 
scores between groups. Not outlined in the table; there were no 
group differences for family history.
The positive PANSS component scores differed among 
groups at all follow-up points post-baseline, with PUs exhibiting 
significantly higher symptom levels. The duration of use of 
antipsychotics or psychotherapy over the 10-year period did 
not differ between users and NUs. There were differences in 
time spent in hospital, both on a yearly basis (p < 0.048) and 
cumulatively (p = 0.048). In addition, substance users spent more 
time in psychosis, both per year (CU > NU p = 0.011; PU > SU p = 
0.024) and cumulatively (CU > NU p = 0.011; PU > SU p = 0.024). 
Mean values and 95% CI for the neurocognitive indices shown over 
time in the groups are provided in the Supplementary Material.
Motor Speed
There were no group differences at baseline for motor speed 
(Table 2). LME modeling showed that development over time 
was significantly different between groups. SUs performed better 
over time (t = 2.20; df 433; p = 0.03) compared with all groups. 
TABLE 1 | Baseline characteristics at study inclusion and at 10 years of first-episode psychosis patients across patterns of substance abuse.
N = 195 No (NU)
N = 106
Stop (SU)
N = 26
Episodic (EU)
N = 33
Persistent (PU)
N = 30
Analysis
N % N % N % N % Chi2 df
Male* 48 45 20 77 20 61 23 77 15.1 3
Diagnosis at inclusion
Schizophrenia spectrum 71 67 18 69 26 79 21 70 6
Affective 20 19 2 8 3 9 3 10 6
Other” 15 14 6 23 4 12 6 20
Median Range Median Range Median Range Median Range F Df***
DUP (weeks)** 8 0–520 9 0–416 17 0–468 16 1–555 1.6 191
Mean SD Mean SD Mean SD Mean SD F Df***
Age**** 30.8 10.3 27.5 8.3 21.9 4.0 22.5 4.3 13.2 191
Premorbid adjustment, last score
Social 1.8 1.5 1.5 1.2 1.9 1.3 1.9 1.6 0.4 191
Academic***** 2.2 1.4 2.3 1.3 2.5 1.2 3.0 1.4 2.8 191
PANSS and GAF baseline
Positive 15.3 4.4 16.1 4.9 14.7 3.6 15.2 4.7 0.4 190
Negative 20.2 9.8 20.4 8.1 22.3 9.2 21.3 7.5 0.4 189
GAF function.007 (SU/PU.01) 31.6 10.4 27.8 9.2 33.3 10.5 8.6 1.6 4.2 189
PANSS and GAF at 10 years
Positive comp (NU/PU.035), (SU/PU.018) 8.5 4.1 7.2 3.3 10.2 4.5 11.6 5.5 4.6 130
Negative 15.9 7.2 14.6 6.3 17.9 6.9 19.5 9.6 1.9 130
GAF function 001 (SU/EU.002) SU/PU.036) 52.2 14.3 62.7 12.0 44.3 14.0 49.0 17.2 5.5 130
*p < .002; “Other diagnoses: delusional disorder (n = 7), brief psychotic disorder (n = 3), organic psychosis (n = 1), psychosis NOS (n = 10); **Reported values are median values, 
while analysis of variance was done with log transformed DUP values; ***All between-group degrees of freedom (df) = 3. Df reported in table concerns within-group df;  
****Post hoc comparisons Scheffe test, pairwise comparisons NU&EU, NU&PU p < .001; *****p < .05; #Post hoc comparisons Scheffe test.
TABLE 2 | Standardized neuropsychological test scores at baseline in first-episode psychosis patients across patterns of substance abuse.
N = 195 No (NU)
N = 106
Stop (SU)
N = 26
Episodic (EU)
N = 33
Persistent (PU)
N = 30
Analysis
Mean SD Mean SD Mean SD Mean SD F p Df within
Neuropsychological index scores
Verbal learning .17 1.1 .01 .82 -.08 .94 −.25 .95 1.4 .241 184
Verbal fluency .03 .96 −.06 1.1 .16 .80 .14 .97 .37 .773 187
Executive function −.43 .89 .12 .87 .06 .74 −.04 1.0 .29 .831 184
Motor speed −.13 .96 .10 1.1 .14 1.1 .32 .89 1.9 .132 188
Trail Making −.07 1.2 −.13 .79 −.12 .98 .42 .67 2.0 .113 183
Composite score .01 .64 −.05 .69 .01 .49 .07 .61 .19 .906 191
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Females had lower scores over time and at baseline (t = −7.07; 
df 208; p = 0.001).
Executive Function
There were no significant group differences for executive functioning.
Verbal Learning
All four groups perform poorer with time on verbal learning. 
SUs had higher scores across all follow-up points (t = 2.00; df 
211; p = 0.05). Poorer premorbid function was associated with 
lower scores (t = −2.57; df 211; p = 0.01). Women performed 
significantly better than men at all follow-up points (t = 4.95; df 
211; p = 0.001). Patients with narrow schizophrenia diagnoses in 
the SUs (t = −2.03; df 211; p = 0.04) and EUs (t = −2.76; df 211; 
p = 0.006) performed poorer than NUs.
Visuomotor Processing
The PUs scored significantly poorer than NUs across all time 
points on visuomotor processing (t = −2.37; df 207; p = 0.020). 
Performance levels were predicted by education where shorter 
length (t = −3.58; df 207; p = 0.001) and poorer premorbid 
adjustment predicted lower scores. Higher age was also a 
predictor of poorer scores (t = 4.63; df 207; p = 0.001).
Verbal Fluency
The SUs scored significantly higher than the NUs on verbal fluency, 
although change over time was parallel (t = 2.21; df 210; p = 0.03). 
There was a significant improvement over time in all groups. 
Longer education (t = 2.23; df 210; p = 0.03), better premorbid 
functioning (t = −2.75; df 210; p = 0.006), and female gender (t = 
2.68; df 210; p = 0.008) were associated with better scores.
Composite Score
There was no significant change over time and no significant 
group differences in overall performances. The composite score 
was significantly associated with longer education (t = 2.73; df 
213; p = 0.006), better premorbid functioning (t = −3.98; df 213; 
p = 0.001), female gender (t = 2.29; df 213; p = 0.022), and lower 
age (t = −2.24; df 213; p = 0.026). Within the SUs (t = −2.32; df 
213; p = 0.022) and EUs (t = −2.34; df 213; p = 0.021), the narrow 
schizophrenia group performed poorer.
In summary, patients who stopped using substances had 
higher motor speed, better verbal learning, and better verbal 
fluency. Persistent users performed significantly worse on 
visuomotor processing, while participants who had never used 
substances had significantly better visuomotor processing and 
poorer verbal fluency. For EUs and SUs, patients with narrow 
schizophrenia diagnoses performed significantly poorer overall.
DISCUSSION
This study is one of the firsts to focus on cognition, substance use, 
and substance-use discontinuation in a sample of FEP patients. 
Our study is longitudinal and includes a large and representative 
sample. The main finding was that those who stop using substances 
early have superior cognitive functioning on several measures 
compared with those who continue using, either persistently 
or episodically. Those who stop using within the first 2 years of 
receiving treatment do as well as, or better than, NUs.
Better performance on cognitive functioning indices were 
associated with better premorbid academic functioning and 
more years of education as well as female gender. Persistent and 
EUs had poorer premorbid academic functioning and were more 
likely to be male. However, both male gender and poor premorbid 
adjustment represent poor prognostic factors in psychosis. Thus, 
it may be challenging to disentangle the effect of poor premorbid 
adjustment from substance use.
For instance, the trail making test and verbal fluency both have 
a strong component of mental control. Trail making part B relies 
heavily on set-shifting ability, and verbal fluency, whereas the F-A-S 
measure of verbal fluency relies on efficient search skills and, hence, 
also mental control. Both these tests were associated with premorbid 
educational attainment, academic adjustment, and substance use. 
Furthermore, mental control is an ability that is often compromised 
in patients with more severe psychotic illnesses. Improvement and 
superior performances in those who stop using substances and 
worse performances in those who continue to use may therefore 
contribute to a growing evidence base suggesting a milder illness 
process in SUs. It has indeed been suggested from other studies that 
substance users may have better cognitive functioning than NUs 
and follow a different path to illness, with a separate starting point 
and trajectory toward psychosis. The finding that verbal fluency 
was impaired in those who never used substances aligns well with 
this: verbal fluency has repeatedly been shown to be a robust and 
central impairment in schizophrenia and other psychoses. Having 
developed psychosis in the absence of the risk factor substance use 
may thus be indicative of a more severe or even more endogenous 
illness process.
Previous findings from this and other studies (45, 66, 71) show 
that patients who stop using have better clinical and functional 
outcomes than both EUs and PUs. One may speculate that 
these patients lack some vulnerabilities present in other groups 
and that perhaps psychosis may even have been avoided in the 
absence of substance use.
Susceptibility to psychosis is considered familial to a certain 
degree, and some family studies have found deficits in verbal 
learning and motor speed (72, 73) in unaffected relatives. We did not 
find any significant difference in the rate of positive family history of 
mental illness in first-degree relatives between groups or diagnostic 
categories. In summary, our findings appear to underscore the 
importance of substance use as an independent risk factor and, more 
malleable than familial risk, trauma, and other known factors. The 
possibility of substantial harm reduction with early discontinuation 
is an important message to clinicians and provides hope for patients 
who struggle with addiction and psychosis.
A longitudinal study such as ours holds several methodological 
limitations. Retest effects in cognitive testing are one of these. 
However, the spacing over a 10-year period with long intervals 
between testing reduces training effects. Since CVLT is the most 
likely candidate for training effects, we also used a parallel version 
at the 10-year follow-up.
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The rate of dropout is high, although we have compensated 
for this by using linear mixed model analyses that account for 
missing data by calculating estimates.
Our main limitation concerns the lack of means for 
controlling patient’s claims of substance-use cessation. This 
information could have provided valuable information in 
terms of further understanding the relationship between 
substance use and cognitive outcomes. Although urine 
toxicology screenings could have strengthened our findings, 
such sampling is considered intrusive by some and might 
have reduced the representability of our sample and increased 
attrition. Furthermore, these measures of sampling have 
limited validity and only for a narrow number of substances. 
We were aware of the possibility of underreporting, and 
therefore, assessments adopted a non-judgmental approach. 
Our impression was that details provided by patients was 
consistent with all other sources of information used in the 
project such as co-lateral information and patient files.
Longitudinal studies of FEP are useful in that they include 
baseline measures of neurocognitive performance thus 
minimizing the confounding effects of chronicity. Our study 
consists of a large representative cohort with patients followed 
up over a longer period than most other longitudinal FEP 
studies and with five repeated assessments of the cognitive 
domains.
The present study demonstrated differences in motor speed 
and verbal indices in patients who discontinued substance use 
early on in their course of treatment. This, as well as previous 
published results indicating that SUs reach levels as good as 
or better than NUs, conveys a powerful message to clinicians. 
Focusing on substance use early is crucial in order to maximize 
the likelihood of good outcomes.
ETHICS STATEMENT
The study was carried out in accordance with the recommendations 
and has been approved by the Regional Committee for Research 
Ethics Health Region 2 (#S95189) and the Regional Committee 
for Research Ethics Health Region East (#1.2007.2177). Data 
inspectorate license: #96/3017-2, #2003/2052. The Regional 
Committee for science ethics region Sjælland: #1-01-83-0002-07. 
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by the 
Regional Commitees for Research ethics (see above).
AUTHOR CONTRIBUTIONS
SF, JJ, TL, IJ, PV, SO, IM, BR, ES, and UH took part in designing 
the study. TL, IJ, IM, SF, ES, UH, and WH collected the data. MW, 
WH, and BA performed the analyses. MW wrote the first draft of the 
manuscript with support from WH, JJ, as well as HS, KB, JR and JB. All 
authors critically reviewed the paper and approved the final version.
FUNDING
This work was supported by Health West, Norway #911369; 
the Norwegian National Research Council #133897/320 and 
#154642/320, the Norwegian Department of Health and Social 
Affairs, and the National Council for Mental Health, Health and 
Rehabilitation #1997/41 and #2002/306, Rogaland County 
and Oslo County. This work was also funded by the Theodore and 
Vada Stanley Foundation and the Regional Health Research 
Foundation for Eastern Region, Denmark; Roskilde County, 
Helsefonden, Lundbeck Pharma, Eli Lily, and Janssen Cilag 
Pharmaceuticals Denmark; the National Alliance for Research 
on Schizophrenia and Depression (NARSAD) distinguished 
investigator award and NIM grant MH-01654 and a NARSAD 
young investigator award; and Health South East #2008001 and 
Health West #200202797-65 and #911313.
ACKNOWLEDGMENTS
The authors want to acknowledge Thomas H. McGlashan, who 
has been a cornerstone in the TIPS study. He had a major role in 
planning and running the study and was principal investigator 
from the start of the study in 1997 until 2013.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: 
https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00495/
full#supplementary-material
REFERENCES
 1. Green MF. What are the functional consequences of neurocognitive deficits in 
schizophrenia? Am J Psychiatry (1996) 153(3):321–30. doi: 10.1176/ajp.153.3.321
 2. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a 
change in focus. JAMA Psychiatry (2013) 70(10):1107–12. doi: 10.1001/
jamapsychiatry.2013.155
 3. Bahorik AL, Newhill CE, Eack SM. Neurocognitive functioning of 
individuals with schizophrenia: using and not using drugs. Schizophr Bull 
(2014) 40(4):856–67. doi: 10.1093/schbul/sbt099
 4. Bora E, Lin A, Wood SJ, Yung AR, McGorry PD, Pantelis C. Cognitive 
deficits in youth with familial and clinical high risk to psychosis: a systematic 
review and meta-analysis. Acta Psychiatr Scand (2014) 130(1):1–15. doi: 
10.1111/acps.12261
 5. Morrens M, Hulstijn W, Sabbe B. Psychomotor slowing in schizophrenia. 
Schizophr Bull (2007) 33(4):1038–53. doi: 10.1093/schbul/sbl051
 6. Bervoets C, Docx L, Sabbe B, Vermeylen S, Van Den Bossche MJ, Morsel A, 
et al. The nature of the relationship of psychomotor slowing with negative 
symptomatology in schizophrenia. Cogn Neuropsychiatry (2014) 19(1):36–
46. doi: 10.1080/13546805.2013.779578
 7. Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in 
patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry 
Rev (2014) 59(1):13–7. doi: 10.1177/070674371405900104
 8. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive 
impairment in schizophrenia: consistent over decades and around the world. 
Schizophr Res (2013) 150(1):42–50. doi: 10.1016/j.schres.2013.07.009
 9. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, 
et al. Static and dynamic cognitive deficits in childhood preceding adult 
10 Years Outcome in FEP PatientsWeibell et al.
8 July 2019 | Volume 10 | Article 495Frontiers in Psychiatry | www.frontiersin.org
schizophrenia: a 30-year study. Am J Psychiatry (2010) 167(2):160–9. doi: 
10.1176/appi.ajp.2009.09040574
 10. Holmen A, Juuhl-Langseth M, Thormodsen R, Melle I, Rund BR. 
Neuropsychological profile in early-onset schizophrenia-spectrum disorders: 
measured with the MATRICS battery. Schizophr Bull (2010) 36(4):852–9. 
doi: 10.1093/schbul/sbn174
 11. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. 
Neurocognition in first-episode schizophrenia: a meta-analytic review. 
Neuropsychology (2009) 23(3):315–36. doi: 10.1037/a0014708
 12. Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among 
psychiatric outpatients: focus on cognition, social role functioning, and 
psychiatric status. J Nervous Ment Dis (2003) 191(5):300–8. doi: 10.1097/01.
NMD.0000066152.87832.A9
 13. McCleery A, Addington J, Addington D. Substance misuse and cognitive 
functioning in early psychosis: a 2 year follow-up. Schizophr Res (2006) 
88(1–3):187–91. doi: 10.1016/j.schres.2006.06.040
 14. Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, et al. 
Corerlates of substance abuse in patients with first-episode schizophrenia 
and schizoaffective disorder. Acta Psychiatr Scand (2001) 104:367–374. doi: 
10.1034/j.1600-0447.2001.00452.x
 15. Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, 
et al. Lifetime antipsychotic medication and cognitive performance in 
schizophrenia at age 43 years in a general population birth cohort. Psychiatry 
Res (2017) 247:130–8. doi: 10.1016/j.psychres.2016.10.085
 16. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, 
et al. Antipsychotic medication and cognitive function in schizophrenia. 
Schizophr Res (2006) 86(1–3):138–46. doi: 10.1016/j.schres.2006.05.004
 17. Woodward ND, Purdon SE, Meltzer HY. Zald DH. A meta-analysis of 
neuropsychological change to clozapine, olanzapine, quetiapine, and 
risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 8(3):457–
72. doi: 10.1017/S146114570500516X
 18. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. 
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function 
in early psychosis: a randomized, double-blind 52-week comparison. Am J 
Psychiatry (2007) 164(7):1061–71. doi: 10.1176/ajp.2007.164.7.1061
 19. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, Mata I, Ayesa 
R, Ramirez-Bonilla M, et al. Neurocognitive effectiveness of haloperidol, 
risperidone, and olanzapine in first-episode psychosis: a randomized, 
controlled 1-year follow-up comparison. J Clin Psychiatry (2009) 70(5):717–
29. doi: 10.4088/JCP.08m04634
 20. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, et al. 
Substance use in a population-based clinic sample of people with first-
episode psychosis. Br J Psychiatry (2007) 190:515–20. doi: 10.1192/bjp.
bp.106.024448
 21. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. 
Substance misuse in first-episode psychosis: 15-month prospective follow-up 
study. Br J Psychiatry (2006) 189:229–34. doi: 10.1192/bjp.bp.105.017236
 22. Wisdom JP, Manuel JI, Drake RE. Substance use disorder among people 
with first-episode psychosis: a systematic review of course and treatment. 
Psychiatr Serv (2011) 62(9):1007–12. doi: 10.1176/ps.62.9.pss6209_1007
 23. D’Souza C, Cho H, Perry E. A cannabinoid model for psychosis, dopamine-
cannabinoid interaction and implications for schizophrenia. Cambridge: 
Cambridge University Press (2004). 
 24. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, 
Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: 
implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 
57(6):594–608. doi: 10.1016/j.biopsych.2004.12.006
 25. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on 
neurocognition in schizophrenia: a meta-analysis. Schizophr Res (2011) 
128(1–3):111–6. doi: 10.1016/j.schres.2011.02.017
 26. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: 
a selective overview of neurobiological and cognitive underpinnings. 
Psychiatry Clin Neurosci (2013) 67(6):367–83. doi: 10.1111/pcn.12072
 27. Loberg EM, Helle S, Nygard M, Berle JO, Kroken RA, Johnsen E. 
The Cannabis Pathway to non-affective psychosis may reflect less 
neurobiological vulnerability. Front Psychiatry (2014) 5:159. doi: 10.3389/
fpsyt.2014.00159
 28. Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S, 
Davidson M, et al. Comorbid substance abuse in first-episode schizophrenia: 
effects on cognition and psychopathology in the EUFEST study. Schizophr 
Res (2013) 147(1):132–9. doi: 10.1016/j.schres.2013.03.001
 29. Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, et al. 
The impact of cannabis use on cognitive functioning in patients with 
schizophrenia: a meta-analysis of existing findings and new data in a first-
episode sample. Schizophr Bull (2012) 38(2):316–30. doi: 10.1093/schbul/
sbq079
 30. Coulston CM, Perdices M, Tennant CC. The neuropsychology of cannabis 
and other substance use in schizophrenia: review of the literature and 
critical evaluation of methodological issues. Aust N Z J Psychiatry (2007) 
41(11):869–84. doi: 10.1080/00048670701634952
 31. Rodriguez-Jimenez R, Bagney A, Martinez-Gras I, Ponce G, Sanchez-Morla 
EM, Aragües M, et al. Executive function in schizophrenia: influence of 
substance use disorder history. Schizophr Res (2010) 118(1–3):34–40. doi: 
10.1016/j.schres.2009.09.025
 32. Leeson VC, Harrison I, Ron MA, Barnes TRE, Joyce EM. The Effect of 
cannabis use and cognitive reserve on age at onset and psychosis outcomes 
in first-episode schizophrenia. Schizophr Bull (2012) 38(4):873–80. doi: 
10.1093/schbul/sbq153
 33. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz NN, 
et  al. Neurocognitive functioning in patients with first-episode schizophrenia: 
results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin 
Neurosci (2006) 256(7):442–51. doi: 10.1007/s00406-006-0667-1
 34. Stirling J, White C, Lewis S, Hopkins R, Tantam D, Huddy A, et al. 
Neurocognitive function and outcome in first-episode schizophrenia: a 
10-year follow-up of an epidemiological cohort. Schizophr Res (2003) 65(2–3): 
75–86. doi: 10.1016/S0920-9964(03)00014-8
 35. Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TR, 
et al. Discrimination learning, reversal, and set-shifting in first-episode 
schizophrenia: stability over six years and specific associations with 
medication type and disorganization syndrome. Biol Psychiatry (2009) 
66(6):586–93. doi: 10.1016/j.biopsych.2009.05.016
 36. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE. Ten year longitudinal study of 
neuropsychological functioning subsequent to a first episode of schizophrenia. 
Schizophr Res (2005) 78(1):27–34. doi: 10.1016/j.schres.2005.05.010
 37. Gold S, Arndt S, Nopoulos P, O’Leary DS, Andreasen NC. Longitudinal 
study of cognitive function in first-episode and recent-onset schizophrenia. 
Am J Psychiatry (1999) 156(9):1342–8. doi: 10.1176/ajp.156.9.1342
 38. Oie M, Sundet K, Rund BR. Neurocognitive decline in early-onset 
schizophrenia compared with ADHD and normal controls: evidence from 
a 13-year follow-up study. Schizophr Bull (2010) 36(3):557–65. doi: 10.1093/
schbul/sbn127
 39. Barder HE, Sundet K, Rund BR, Evensen J, Haahr U, Ten Velden Hegelstad 
W, et al. Ten year neurocognitive trajectories in first-episode psychosis. Front 
Hum Neurosci (2013) 7:643. doi: 10.3389/fnhum.2013.00643
 40. Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. 
Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J 
Psychiatry (2008) 192(4):248–57. doi: 10.1192/bjp.bp.106.029009
 41. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode 
psychosis: a systematic review of the literature. Aust N Z J Psychiatry (2011) 
45(2):93–108. doi: 10.3109/00048674.2010.541418
 42. Rund BR. A review of longitudinal studies of cognitive functions in 
schizophrenia patients. Schizophr Bull (1998) 24(3):425–35. doi: 10.1093/
oxfordjournals.schbul.a033337
 43. Addington J, Addington D. Patterns, prdictors and impact of substance use 
in early psychosis: a longitudinal study. Acta Psychiatr Scand (2007) 115:304–
9. doi: 10.1111/j.1600-0447.2006.00900.x
 44. Drake RE, McHugo GJ, Xie HY, Fox M, Packard J, Helmstetter B. Ten-
year recovery outcomes for clients with co-occurring schizophrenia and 
substance use disorders. Schizophr Bull (2006) 32(3):464–73. doi: 10.1093/
schbul/sbj064
 45. Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M. 
Does giving up substance use work for patients with psychosis? A 
systematic meta-analysis. Aust N Z J Psychiatry (2012) 46(9):826–39. doi: 
10.1177/0004867412440192
10 Years Outcome in FEP PatientsWeibell et al.
9 July 2019 | Volume 10 | Article 495Frontiers in Psychiatry | www.frontiersin.org
 46. González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, 
et al. Cannabis and first-episode psychosis: different long-term outcomes 
depending on continued or discontinued use. Schizophr Bull (2011) 
37(3):631–9. doi: 10.1093/schbul/sbp126
 47. Weibell MA, Hegelstad WTV, Auestad B, Bramness J, Evensen J, Haahr U, et al. 
The effect of substance use on 10-year outcome in first-episode psychosis. 
Schizophr Bull (2017) 11:843–51. doi: 10.1093/schbul/sbw179
 48. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. 
Substance abuse in first-episode non-affective psychosis. Schizophr Res 
(2006) 88(1–3):55–62. doi: 10.1016/j.schres.2006.07.018
 49. Rund BR, Barder HE, Evensen J, Haahr U, ten Velden Hegelstad W, Joa I, et al. 
Neurocognition and duration of psychosis: a 10-year follow-up of first-episode 
patients. Schizophr Bull (2016) 42(1):87–95. doi: 10.1093/schbul/sbv083
 50. Rund BR, Melle I, Friis S, Johannessen JO, Larsen TK, Midbøe LJ, et al. 
The course of neurocognitive functioning in first-episode psychosis and 
its relation to premorbid adjustment, duration of untreated psychosis, and 
relapse. Schizophr Res (2007) 91(1–3):132–40. doi: 10.1016/j.schres.2006. 
11.030
 51. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, 
et al. Reducing the duration of untreated firs-episode psychosis: effects on 
clinical presentation. Arch Gen Psychiatry (2004) 61:143–50. doi: 10.1001/
archpsyc.61.2.143
 52. American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders. 4th ed. Washington DC: American Psychiatric Association (2000). 
 53. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull (1987) 13(2):261–76. doi: 
10.1093/schbul/13.2.261
 54. Pedersen G, Hagtvet K, Karterud S. Generalizability studies of the Global 
Asssessment of Functionin- Split version. Compr Psychiatry (2007) 48(1):88–
94. doi: 10.1016/j.comppsych.2006.03.008
 55. Bentsen H, Notland TH, Boye, B, Bjørge H, Lersbryggen AB, Oskarsson 
KH, et al. The interrater reliability of the Positive and Negative Syndrome 
Scale (PANSS). Int J Methods Psychiatr Res (1996) 6:227–35. doi: 10.1002/
(SICI)1234-988X(199612)6:4<227::AID-MPR162>3.3.CO;2-A
 56. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid 
adjustment in chronic schizophrenia. Schizophr Bull (1982) 8(3):470–84. doi: 
10.1093/schbul/8.3.470
 57. Larsen TK, Friis S, Haahr U, Johannessen JO, Melle I, Opjordsmoen S, et al. 
Premorbid adjustment in first-episode non-affective psychosis: distinct 
patterns of pre-onset course. Br J Psychiatry (2004) 185:108–15. doi: 10.1192/
bjp.185.2.108
 58. Delis DC, Kramer JH, Kapla E, Ober BA. The California Verbal Learning Test. 
2nd ed. San Antonio Texas: The Psychological Corporation (2000). 
 59. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting 
Test Manual: Revised and Expanded. New York NY: Oxford University Press 
(1993). 
 60. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological 
Tests: Administration, Norms and Commentary, 2nd ed. New York: Oxford 
University Press (1998).
 61. Friis S, Sundet K, Rund BR, Vaglum P, McGlashan TH. Neurocognitive 
dimensions characterising patients with first-episode psychosis. Br J 
Psychiatry Suppl (2002) 181:s85–s90. doi: 10.1016/S0924-9338(02)80241-3
 62. Friis S, Larsen TK, Melle I, Opjordsmoen S, Johannessen JO, Haahr U, et al. 
Methodological pitfalls in early detection studies  - the NAPE Lecture 2002. 
Nordic Association for Psychiatric Epidemiology. Acta Psychiatr Scand (2003) 
107(1):3–9. doi: 10.1034/j.1600-0447.2003.02600.x
 63. Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-
term follow-up of the TIPS early detection in psychosis study: effects on 
10-year outcome. Am J Psychiatry (2012) 169(4):374–80. doi: 10.1176/appi.
ajp.2011.11030459
 64. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated treatment for dual 
disorders. New York: The Guilford Press (2003). 
 65. Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, González-
Pinto A, et al. Cannabis use in children and adolescents with first episode 
psychosis: influence on psychopathology and short-term outcome 
(CAFEPS study). Schizophr Res (2009) 113(2–3):129–37. doi: 10.1016/j.
schres.2009.04.005
 66. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The 
impact of substance use disorders on clinical outcome in 643 patients with 
first-episode psychosis. Acta Psychiatr Scand (2005) 112(2):141–8. doi: 
10.1111/j.1600-0447.2005.00554.x
 67. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and 
outcome of recent onset psychosis. Eur Psychiatry (2005) 20(4):349–53. doi: 
10.1016/j.eurpsy.2004.09.013
 68. Archie S, Rush BR, Akhtar-Danesh N, Norman R, Malla A, Roy P, et al. 
Substance use and abuse in first-episode psychosis: prevalence before and 
after early intervention. Schizophr Bull (2007) 33(6):1354–63. doi: 10.1093/
schbul/sbm011
 69. SPSS for Windows (11.5.1) [computer program]. Version. Chicago: SPSS inc.; 
2001. 
 70. R: A language and environment for statistical computing [computer program]. 
Version. Vienna, Austria; 2017. 
 71. Strakowski S, DelBello M, Fleck D, Adler C, Anthenelli R, Arnold L, et al. 
Effects of co-occurring cannabis use disorders on the course of bipolar 
disorder after a first hspitalization for mania. Arch Gen Psychiatry (2007) 
64(1):57–64. doi: 10.1001/archpsyc.64.1.57
 72. Hoff AL, Svetina C, Maurizio AM, Crow TJ, Spokes K, DeLisi LE. Familial 
cognitive deficits in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 
(2005) 133B(1):43–9. doi: 10.1002/ajmg.b.30120
 73. Chen YL, Chen YH, Lieh-Mak F. Semantic verbal fluency deficit as a familial 
trait marker in schizophrenia. Psychiatry Res (2000) 95(2):133–48. doi: 
10.1016/S0165-1781(00)00166-9
Conflict of Interest Statement: SO has given advice to Otsuka and Lundbeck and 
lectured in meetings organized by those companies. SF has received an honorarium 
as a data consultant for RAND Corporation for a project sponsored by Janssen-
Cilag pharmaceutical company. The remaining authors declare that the research 
was conducted in the absence of any commercial or financial relationships that 
could be construed as a potential conflict of interest.
Copyright © 2019 Weibell, Johannessen, Auestad, Bramness, Brønnick, Haahr, Joa, 
Larsen, Melle, Opjordsmoen, Rund, Røssberg, Simonsen, Vaglum, Stain, Friis and 
Hegelstad. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) and the copyright owner(s) 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
